Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Gamma secretase inhibitor C1 may be of potential significance for symptoms of Alzheimer’s

Staff Writer
Staff Writer 3 years ago
Updated 2020/04/03 at 11:39 PM
Share
SHARE

Researchers at Rensselaer Polytechnic Institute have demonstrated a drug candidate of potential significance for combating the principle pathology of Alzheimer’s disease. The results appeared in the journal Chemical Communications.

The candidate in focus, identified as the compound C1, inhibits the enzyme gamma secretase from its role in the production of amyloids and subsequently fibrils, a hallmark indicator of Alzheimer’s disease.

C1 received its focus as a promising drug candidate after various screenings identifying a compound targeting the amyloid precursor protein substrate, which would prevent amyloid production by inhibiting gamma secretase. The screenings were initiated by Chunyu Wang, a researcher at Rensselaer Polytechnic Institute.

“Historically, drug trials for gamma secretase inhibitors failed because traditional enzyme inhibitors have severe side effects. They stopped all of the normal functions of gamma secretase,” Wang explained.


“Our compound binds to the cleavage site of the precursor protein instead of the enzyme itself, which may avoid many problems associated with traditional enzyme inhibitors.”

Deepak Vashishth, another researcher at Rensselaer Polytechnic Institute, added: “With a new approach to tackling the principal pathology of Alzheimer’s disease, Chunyu’s work is generating a fresh roster of drug candidates with enormous promise. His works speaks to the power of the interdisciplinary culture of research at CBIS, and we are pleased with this early result.”

Photo: iStock

You Might Also Like

New study explores test that can detect Alzheimer’s years before diagnosis

New research explores the association between viral infection and Alzheimer’s disease

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

New research finds Alzheimer’s risk factors affect males and females very differently

TAGGED: C1, gamma-secretase, Alzheimer's disease, cognition
Staff Writer February 3, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Walnuts could lower the severity of cognitive decline among elderly people
Next Article Low sleep duration linked to affective symptoms, impulsivity & decreased cognitive function in children

Recommended

Clinical

New study explores test that can detect Alzheimer’s years before diagnosis

1 Min Read
Health

New research explores the association between viral infection and Alzheimer’s disease

1 Min Read
Clinical

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

1 Min Read
Clinical

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?